Antiretroviral Therapy News

• AIDS 2018Benefits, Risks of Dolutegravir Center Stage at AIDS 2018 Potentially game-changing data on HIV treatment will be presented at the International AIDS Conference, but policies that make treatment and prevention difficult will also be discussed.
  Medscape Medical News, July 2018
• Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV Fixed-dose bictegravir-emtricitabine-tenofovir (Biktarvy) maintains virologic suppression in adults with HIV-1 who are switched from dolutegravir-abacavir-lamivudine or from boosted protease inhibitor-based regimens, according to results from two noninferiority trials.
  Reuters Health Information, July 2018
• Hong Kong Scientists Say New Research Points to Universal Antibody Drug for HIV A team of AIDS researchers in Hong Kong says its new research, tested on mice, indicates a functional cure for HIV, eventually leading to a new antibody that could be used for both prevention and treatment.
  Reuters Health Information, June 2018
• Stigma May Keep Women From Using HIV Pre-Exposure Prophylaxis Fear of others thinking they're promiscuous, or that they're already infected with HIV, is a barrier to many women who might benefit from pre-exposure prophylaxis (PrEP), a U.S. study suggests.
  Reuters Health Information, June 2018
• AIDS 2018GSK's Two-Drug HIV Treatment Meets Main Goal in Late Stage Studies GlaxoSmithKline's two-drug treatment for HIV met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.
  Reuters Health Information, June 2018
• White Matter Hyperintensities Increased in Patients With HIV and Diabetes
  Reuters Health Information, June 2018
• Victims of Fake AIDS Treatment Sue Gambia's Ex-ruler
  Reuters Health Information, May 2018
• Increased Risk of Cardiovascular Disease With Darunavir Cumulative use of ritonavir-boosted darunavir, a contemporary protease inhibitor used to treat HIV, is associated with an increasing risk of cardiovascular disease, according to results from the D:A:D study.
  Reuters Health Information, May 2018
• Non-AIDS Cancers Expected to Dominate in HIV-infected Adults by 2030
  Reuters Health Information, May 2018
• ACOG 2018HIV Vertical Transmission Rates Comparable With PI- and INSTI-based ART
  Reuters Health Information, May 2018
• ART With Tenofovir Backbone Not Linked to Worse Outcomes
  Reuters Health Information, May 2018
• Mosaic HIV-1 Immunogens Elicit Specific Immune Responses in Healthy Volunteers Mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara (MVA) vector elicit HIV-1-specific immune responses in healthy, uninfected volunteers, researchers report.
  Reuters Health Information, April 2018
• Doravirine Effective in Treatment-naive Adults With HIV Doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), is as effective as ritonavir-boosted darunavir, a protease inhibitor, in treatment-naive adults infected with HIV-1, according to results from the DRIVE-FORWARD trial.
  Reuters Health Information, April 2018
• Glecaprevir/pibrentasvir Treats Hepatitis C in HIV-coinfected Individuals The direct-acting antiviral (DAA) combination glecaprevir/pibrentasvir is effective for treating hepatitis C virus (HCV) infection in individuals coinfected with HIV-1, according to results from the non-randomized, open-label phase 3 EXPEDITION-2 trial.
  Reuters Health Information, April 2018
• Use of HIV-Prevention Drug Grows, but Lags Among Nonwhites Across the US, PrEP use is rising significantly. Blacks and Latinos, however, have been slow to embrace the medication even though HIV infection rates among them are much higher than among whites.
  Kaiser Health News, March 2018
• Tenofovir Alafenamide Plus Emtricitabine Effective, Safe in HIV In HIV patients, combination therapy with tenofovir alafenamide and emtricitabine is non-inferior to that of abacavir plus lamivudine, according to a manufacturer-sponsored trial.
  Reuters Health Information, March 2018
• CROIHIV Incidence Drops Below 2% in Vaginal Ring Follow-ups The vaginal ring was moderately protective against HIV in early studies. Now, interim data from two follow-up studies show that the incidence has dropped, but why this happened is a subject of debate.
  Medscape Medical News, March 2018
• CROI'Urgent Action' Needed to Prevent HIV in Black Americans New estimates show that half a million black Americans qualify for the HIV prevention pill, but only 1% of those have been prescribed PrEP.
  Medscape Medical News, March 2018
• Daily TB Therapy Best in HIV-positive Patients Daily anti-tuberculosis therapy works better than thrice-weekly dosing in reducing failures and acquired rifampicin resistance among HIV-infected patients with TB receiving antiretroviral therapy, according to a study from India.
  Reuters Health Information, March 2018
• Tenofovir Gel Less Effective in Women With Genital Inflammation Tenofovir gel is less effective in preventing HIV in women with genital inflammation, according to a post hoc analysis of data from the CAPRISA 004 study.
  Reuters Health Information, March 2018
• Pharmacokinetics of Tenofovir Vaginal Gel Differs by Age The pharmacokinetics of tenofovir vaginal gel differs between premenopausal and postmenopausal women, likely because of differences in the state of the cervicovaginal mucosa, researchers report.
  Reuters Health Information, February 2018